Ontario agrees to pay for J&J's Zytiga pill; Lundbeck asks for EU nod on its new antidepressant;

 @FiercePharma: Bayer CEO tells Boston audience that pricing pressure threatens innovation--but U.S. isn't the problem. More | Follow @FiercePharma

> The Canadian state of Ontario has agreed to foot the bill for Johnson & Johnson's ($JNJ) new prostate cancer pill Zytiga. Report

> Lundbeck filed for European approval of its new antidepressant, with plans to file in the U.S. by year's end. Report

> FDA sent Jazz Pharmaceuticals a warning letter, saying that a patient brochure supporting the antipsychotic drug FazaClo was false or misleading because it left out or minimized the drug's risks and overstated its efficacy. Report

> The U.K.'s pharma industry trade group cleared Sanofi ($SNY) of wrongdoing after an ex-employee accused the French drugmaker of promoting drugs for off-label use, among other infractions. Report

> Free trade negotiations between Canada and the E.U. have bogged down in fears that extended patent protections could push up the costs of prescription drugs. Report

> Drug distributor Harvard Drug Group is buying an undisclosed generics manufacturer for $117 million, Standard & Poor's reports. Report

> Glenmark Pharmaceuticals won tentative FDA approval for its version of the Merck ($MRK) migraine treatment Maxalt. Report

Medical Device News

 @FierceMedDev: We are in the FMD Fierce 15 final stretch. Winners revealed on Oct. 2 at AdvaMed 2012 and in FMD. Innovators all. More | Follow @FierceMedDev

 @MarkHFierce: In Mass., Dx, Rx and device companies can now cover modest meals and drinks, thanks to relaxed gift ban regs. Story | Follow @MarkHFierce

 @DamianFierce: Seattle startup Innovative Pulmonary has a new CEO and $10.6M in financing. News | Follow @DamianFierce

> Survey: Pharmas value tech when choosing Dx partners. More

> Conflicting arguments abound on the device tax's merits. Item

> Given Imaging soars after filing for Japanese approval. Article

Biotech News

 @FierceBiotech: Slideshow: FierceBiotech's 2012 Fierce 15 at BioPharm America 2012. Slideshow | Follow @FierceBiotech

 @JohnCFierce: Novartis grabs a $665M option to buy sickle cell disease biotech--Selexys who? Story | Follow @JohnCFierce

 @RyanMFierce: MacroGenics banks $20M in potential $1.1B cancer drugs deal with Servier. Article | Follow @RyanMFierce

> NYC coup: Roche picks Big Apple site for new R&D home. News

> Foundation Medicine hauls in $42.5M round to back commercialization effort. Story

> Third Rock bankrolls a new biotech to tackle genetic heart disease. News

Vaccines News

> Cardiff University works on anthrax vaccine for NATO. Item

> Emory snags $6M for HIV/AIDS vaccine research. Article

> Software magnate sinks $104M into vaccine research. More

> Obesity vaccine hits obstacle. Story

Pharma Manufacturing News

> Wholesaler McKesson faces new price-manipulation suit. Story

> Gerresheimer glass plant adds line, new furnace. Article

> Regulators OK Recipharm Monts filling expansion. More

> Florida man tied to cargo thefts ordered to forfeit $55M. News

And Finally... The Congressional Budget Office now estimates that 6 million Americans will pay the penalty for failing to buy health insurance, partly because of higher unemployment. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.